Avalyn Pharma (NASDAQ:AVLN) Share Price Crosses Below Fifty Day Moving Average on Analyst Downgrade

Avalyn Pharma logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Avalyn Pharma shares fell below their 50-day moving average after trading as low as $27.04; they last traded at $27.92. Morgan Stanley cut its price target from $57 to $53 but maintained an Overweight rating.
  • Analyst views remain broadly positive: the stock has a “Moderate Buy” consensus rating and a $59.20 average price target, despite one Sell rating.
  • The company reported a quarterly loss of $0.67 per share, missing the analyst consensus estimate of a $0.64 loss per share.
  • Interested in Avalyn Pharma? Here are five stocks we like better.

Avalyn Pharma Inc. (NASDAQ:AVLN - Get Free Report) shares passed below its 50-day moving average during trading on Tuesday after Morgan Stanley lowered their price target on the stock from $57.00 to $53.00. The stock has a 50-day moving average of $28.32 and traded as low as $27.04. Morgan Stanley currently has an overweight rating on the stock. Avalyn Pharma shares last traded at $27.92, with a volume of 453,013 shares changing hands.

AVLN has been the subject of a number of other reports. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Avalyn Pharma in a research report on Wednesday, November 11th. Wall Street Zen upgraded shares of Avalyn Pharma from a "sell" rating to a "hold" rating in a report on Saturday. Finally, Raymond James Financial started coverage on shares of Avalyn Pharma in a research report on Friday, October 2nd. They issued an "outperform" rating and a $60.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $59.20.

View Our Latest Stock Analysis on Avalyn Pharma

Insider Transactions at Avalyn Pharma

In other news, insider Fmr Llc sold 53,454 shares of the business's stock in a transaction that occurred on Tuesday, November 10th. The stock was sold at an average price of $30.21, for a total transaction of $1,614,845.34. Following the completion of the sale, the insider owned 2,056,081 shares in the company, valued at $62,114,207.01. The trade was a 2.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Hedge Funds Weigh In On Avalyn Pharma

Large investors have recently made changes to their positions in the company. Soleus Capital Management L.P. lifted its holdings in Avalyn Pharma by 143.2% during the 3rd quarter. Soleus Capital Management L.P. now owns 1,019,000 shares of the company's stock worth $29,031,000 after purchasing an additional 600,000 shares during the last quarter. State Street Corp grew its holdings in Avalyn Pharma by 73.7% in the 3rd quarter. State Street Corp now owns 554,004 shares of the company's stock valued at $15,784,000 after buying an additional 235,009 shares in the last quarter. Profund Advisors LLC acquired a new position in Avalyn Pharma in the 3rd quarter valued at $668,000. China Universal Asset Management Co. Ltd. bought a new position in Avalyn Pharma during the 3rd quarter worth $29,000. Finally, Manchester Capital Management LLC bought a new position in Avalyn Pharma during the 3rd quarter worth $36,000.

Avalyn Pharma Trading Down 6.2%

The company has a debt-to-equity ratio of 0.04, a quick ratio of 25.76 and a current ratio of 25.76. The stock has a market cap of $1.24 billion and a PE ratio of -1.22. The business has a 50-day simple moving average of $28.32.

Avalyn Pharma (NASDAQ:AVLN - Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.64) by ($0.03). Sell-side analysts predict that Avalyn Pharma Inc. will post -3.87 earnings per share for the current year.

About Avalyn Pharma

(Get Free Report)

Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled treatments for pulmonary fibrosis, including idiopathic pulmonary fibrosis and other progressive fibrotic lung diseases. Its approach is designed to deliver medicine directly to the lungs. The company's pipeline includes AP01, an investigational inhaled formulation of pirfenidone, and AP02, an investigational inhaled formulation of nintedanib. Both medicines are based on drugs used in oral form for pulmonary fibrosis, but Avalyn's inhaled candidates are being studied as potential alternatives to oral treatment.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Avalyn Pharma Right Now?

Before you consider Avalyn Pharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avalyn Pharma wasn't on the list.

While Avalyn Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines